Like many other great discoveries made in science, chance played an important role in the last article published in Cancer Cell by a team of researchers from the Signalling and Cell Cycle Laboratory at IRB Barcelona. "I think we were lucky, but we also knew how to take advantage of our luck," says the biochemist Begoña Cánovas, co-first author of the article, together with Ana Igea.
This success story started back in 2011 when Angel R. Nebreda’s Signalling and Cell Cycle Laboratory moved from CNIO (Madrid) to IRB Barcelona. Among many other things (from big machines to tiny gene copies), they brought with them some mice that were about to be discarded. They had been...
A new study by researchers at IRB Barcelona demonstrates that myeloid cells, which belong to the leucocyte family and form part of the innate immune system, use p38 protein signalling to support inflammation-associated colon cancer.
Published in EMBO Molecular Medicine, the study by Angel R. Nebreda suggests that inhibition of the p38 pathway in myeloid cells may be a useful therapeutic approach, especially in tumours associated with chronic inflammation.
This weekend the Ciutadella Park will be hosting this event, which will showcase 230 scientific activities aimed at the general public.
IRB Barcelona will be participating through two workshops and a micro-talk, related to microscopy, cancer research and ageing.
La Voz de Galicia, TV3, 8TV, among other media, have interviewed Begoña Cánovas, the first author of a recent study led by IRB Barcelona and published in the journal Cancer Cell. The study identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
Link to TV3
Link to 8TV
El País, Ara, La Razón, El Economista, Medical Xpress, News-Medical, among other national and international media, have published an article about recent research led by IRB Barcelona, which reveals a new protective mechanism for tumour cells in breast cancer and identifies novel therapeutic targets to treat this disease.
Link to El País
Link to El Economista
A study on breast cancer conducted at IRB Barcelona identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.
p38 blockage has been shown to increase the death of tumour cells, thus causing tumours to shrink.
The combination of p38 inhibitors with chemotherapeutic drugs (taxanes) strengthens, accelerates or prolongs the antitumour effect in patient-derived tumours grown in mice.
Xavier Salvatella, ICREA researcher at IRB Barcelona, proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.
The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.
The technology supplement Innovadores of the newspaper El Mundo has echoed on the award of 220,000 euros to three biomedical innovation projects underway at IRB Barcelona. This funding has been given by the Agency for Management and University and Research Grants (AGAUR, acronym in Catalan) of the Catalan Government, with the support of ERDFs.
The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.
The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.
On May 27-28, the Barcelona Science Festival will bring a hundred science activities to the Parc de la Ciutadella.
IRB Barcelona is to participate in the Festival by giving a talk on Network Medicine and holding two workshops for a wide range of public.